Status:
COMPLETED
Reversal of Moderate or Superficial Neuromuscular Blockade Induced by Cisatracurium
Lead Sponsor:
Pontificia Universidade Catolica de Sao Paulo
Conditions:
Neostigmine
Neuromuscular Blocking Agents
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The administration of acetylcholinesterase inhibiting agents (such as neostigmine) has been used to reverse the muscle paralysis induced by non-depolarizing neuromuscular blocking agents. It is not we...
Detailed Description
INTRODUCTION One of the most frequent events after performing general anesthesia is the incomplete recovery from NMB. 1 Unfortunately, in addition to the unpleasant and unwanted sensation, post-operat...
Eligibility Criteria
Inclusion
- Patients aged between 18 and 65 years
- Undergoing general anesthesia for nose and ear surgery
- Physical status according to the American Society of Anesthesiologists I and II
Exclusion
- Refusal to participate in the study
- Presence of kidney, liver or neuromuscular disease
- Contraindication to the use of any of the drugs used in the study
- Body mass index (BMI) ≥ 30
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 21 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04920682
Start Date
June 1 2021
End Date
August 21 2021
Last Update
May 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Santa Lucina Hospital
Sorocaba, São Paulo, Brazil, 18030-230